A 15-minute dose-and-discharge non-dual experience vs a 6-hour psilocybin journey — compared on mechanism, protocol, depression evidence, and access.
5-MeO-DMT vs psilocybin is really a comparison of two different visions for psychedelic medicine. One is fast, drug-focused, and built for clinic efficiency. The other is long, therapy-heavy, and already has a regulated legal path in two states. This guide compares them on mechanism, the treatment model, depression evidence, safety, and legal access, so you can see how they actually differ in 2026.
The biggest differences are duration and how the treatment is delivered. 5-MeO-DMT is over in 15 to 30 minutes and is being built as a short, drug-first clinic procedure with little formal psychotherapy. Psilocybin lasts four to six hours and is delivered with substantial preparation and integration support. Psilocybin also has more clinical evidence and the only regulated legal access today, while 5-MeO-DMT is the faster, more commercially efficient model still working through trials.
| Factor | 5-MeO-DMT | Psilocybin |
|---|---|---|
| Duration | ~15–30 minutes. | ~4–6 hours. |
| Main mechanism | Broad serotonin agonist; strong 5-HT1A. | Prodrug of psilocin; mainly 5-HT2A. |
| Experience | Non-visual ego-dissolution. | Visual, emotional, introspective journey. |
| Therapy model | Drug-first; minimal formal psychotherapy in trials. | Therapy-heavy; preparation + integration around the session. |
| Depression evidence | Positive Phase 2b (GH001, BPL-003); Phase 3 pending. | Two positive Phase 3 trials (COMP360) in 2025. |
| Legal access (US) | None outside trials; Schedule I. | Licensed services in Oregon and Colorado; Schedule I federally. |
| Sessions per clinic day | Many (short sessions). | Few (long sessions). |
The clearest strategic difference is how each is delivered. 5-MeO-DMT trials have used a drug-first design with psychological support but no planned course of psychotherapy, treating the medicine more like a procedure than a therapy package.1 Because a session is so short, a clinic could treat many patients in a day.
Psilocybin is the opposite. A single dose lasts several hours and is wrapped in preparation sessions beforehand and integration sessions afterward. That makes it more resource-intensive per patient, but many clinicians see the therapy scaffolding as central to the benefit. This is the core reason companies view 5-MeO-DMT as more commercially scalable — a theme we cover in AtaiBeckley vs GH Research.
Psilocybin has the stronger evidence base today. In 2025, two Phase 3 trials of COMP360 psilocybin met their primary endpoints for treatment-resistant depression, the most advanced psychedelic depression data in the field.2 That puts psilocybin closer to a possible FDA decision than 5-MeO-DMT.
5-MeO-DMT’s data is earlier but striking. GH Research’s GH001 showed a large placebo-adjusted MADRS drop at Day 8, and AtaiBeckley’s BPL-003 met its primary endpoint in a 193-patient Phase 2b. Neither has finished Phase 3. So psilocybin leads on evidence maturity, while 5-MeO-DMT leads on speed and convenience — and neither is FDA-approved yet.
The felt experiences differ as much as the schedules. 5-MeO-DMT tends to dissolve the sense of self quickly and completely, with little visual content — a brief, formless peak. Psilocybin unfolds gradually over hours, with visual and emotional content, memories, and a more navigable, introspective arc.
That difference shapes integration. Psilocybin’s longer, more narrative journey often gives people material to work through in therapy afterward, while 5-MeO-DMT’s intensity can be harder to hold and interpret. Either way, integration therapy helps turn the experience into lasting change.
Only psilocybin has a regulated legal path in the US. Oregon and Colorado run state-licensed psilocybin service centers where adults can take it under supervision without a prescription. 5-MeO-DMT has no such program anywhere in the country; legal access is limited to clinical trials, and some people travel to retreats abroad. Both remain Schedule I at the federal level. For the wider legal map, see what psychedelics are legal in the US.
Psilocybin is the better-evidenced, legally accessible option today, suited to people who want a longer, therapy-supported process and who can reach Oregon or Colorado services.
5-MeO-DMT is the fast, efficient, still-experimental option — attractive to companies for its short session and to patients who may prefer a brief, drug-first procedure once it is approved.
For treatment-resistant depression specifically, psilocybin is further along, but the 5-MeO-DMT race is moving quickly. To keep comparing, read 5-MeO-DMT vs DMT and 5-MeO-DMT vs ayahuasca.
The clearest differences are duration and the treatment model. 5-MeO-DMT works in 15 to 30 minutes and is being developed as a short, drug-first clinic procedure with little formal psychotherapy. Psilocybin lasts 4 to 6 hours and is delivered with substantial preparation and integration therapy around the session. They also act on different receptors: 5-MeO-DMT leans on 5-HT1A, psilocybin on 5-HT2A.
Both show strong early results for treatment-resistant depression, but psilocybin has more trial data. In 2025, two Phase 3 trials of COMP360 psilocybin met their primary endpoints. 5-MeO-DMT has striking Phase 2b data (GH001 and BPL-003) but has not yet completed Phase 3. Neither is FDA-approved, and 'better' will depend on the Phase 3 readouts and each patient's needs.
Psilocybin lasts much longer. A psilocybin session runs about 4 to 6 hours, filling most of a treatment day, while a vaporized 5-MeO-DMT experience is over in 15 to 30 minutes. That short duration is a big reason companies see 5-MeO-DMT as commercially attractive — more patients can be treated per clinic day.
Only psilocybin has a regulated legal path. Oregon and Colorado run licensed psilocybin service centers where adults can take it without a prescription. 5-MeO-DMT has no regulated legal access anywhere in the US; people reach it through clinical trials or retreats abroad. Both remain Schedule I federally.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.